The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Eisai; Lilly; Novartis; Roche
Consulting or Advisory Role - Eisai; Lilly; Novartis; Roche
Travel, Accommodations, Expenses - Eisai; Pfizer; Roche
PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial.
 
Pier Franco Conte
Speakers' Bureau - AstraZeneca; Novartis; Roche/Genentech
Research Funding - Merck Serono (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Novartis
 
Gaia Griguolo
Travel, Accommodations, Expenses - Pfizer
 
Maria Vittoria Dieci
Consulting or Advisory Role - Celgene; Genomic Health; Lilly
Travel, Accommodations, Expenses - Celgene; Pfizer
 
Giancarlo Bisagni
No Relationships to Disclose
 
Alba Ariela Brandes
No Relationships to Disclose
 
Antonio Frassoldati
Honoraria - AstraZeneca; Eisai; Novartis; Pfizer
Travel, Accommodations, Expenses - AstraZeneca; Celgene; Lilly; Novartis; Pfizer; Roche
 
Luigi Cavanna
Consulting or Advisory Role - AstraZeneca; Merck
Travel, Accommodations, Expenses - Celgene; Ipsen; Pfizer
 
Antonino Musolino
No Relationships to Disclose
 
Francesco Giotta
No Relationships to Disclose
 
Anita Rimanti
No Relationships to Disclose
 
Ornella Garrone
Honoraria - Celgene; Eisai; Novartis; Pfizer
Consulting or Advisory Role - Amgen; Celgene; Eisai; Pfizer
Research Funding - Eisai (Inst); Eisai (Inst)
Travel, Accommodations, Expenses - Celgene; Roche
 
Patricia Galvan
No Relationships to Disclose
 
Fara Brasó Maristany
No Relationships to Disclose
 
Enrico Orvieto
No Relationships to Disclose
 
Loredana Urso
No Relationships to Disclose
 
Antonino Maiorana
No Relationships to Disclose
 
Sara Balduzzi
No Relationships to Disclose
 
Roberto D'Amico
No Relationships to Disclose
 
Valentina Guarneri
Consulting or Advisory Role - Lilly; Novartis; Roche
Speakers' Bureau - Lilly; Novartis
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - Celgene; Tesaro
 
Aleix Prat
Employment - Novartis (I)
Honoraria - Daiichi Sankyo; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; NanoString Technologies (Inst); Novartis; Pfizer; Roche
Research Funding - Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics